MediciNova (MNOV)
Develops in-licensed small molecules across neurodegenerative, metabolic, and fibrotic diseases.
$3.00
vs last close−0.31 (−9.24%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 10.67% | 5.25M shares | |
|---|---|---|---|
| 30 holders · as of Jun 30, 2026 | |||
| Other | 89.33% | 43.97M shares | |
| remainder | |||
49.22M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
30 holders · 5.25M shares · 4 new positions · 9 increased · 8 reduced · 4 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Essex Woodlands Management, Inc. | 1.11M | 2.25% | 0 | Aug 4, 2026 |
| BlackRock, Inc. | 752.1K | 1.53% | +46.1K | Aug 7, 2026 |
| Citigroup Inc | 635.7K | 1.29% | 0 | Aug 3, 2026 |
| Vanguard Capital Management LLC | 609.1K | 1.24% | −2.0K | Aug 13, 2026 |
| Geode Capital Management, LLC | 539.3K | 1.10% | −4.5K | Aug 12, 2026 |
| Vanguard Fiduciary Trust Co | 282.6K | 0.57% | +2.0K | Aug 13, 2026 |
| UBS Group AG | 222.2K | 0.45% | 0 | Aug 13, 2026 |
| Renaissance Technologies LLC | 205.4K | 0.42% | +15.5K | Aug 13, 2026 |
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.